D
Direct biologics
Innovative regenerative biologic products leveraging extracellular vesicles and placental-based allografts for advanced therapies
About Direct biologics
Direct Biologics is a pioneering biotechnology company that specializes in the development and manufacturing of regenerative biologic products. The company operates in the healthcare sector, specifically in the field of regenerative therapies. Its primary clients include hospitals and healthcare providers who are seeking innovative solutions for various health conditions, including COVID-19.
The company's flagship product is ExoFlo™, a therapeutic solution derived from bone marrow mesenchymal stem cells (MSC). These cells produce extracellular vesicles, tiny particles that carry proteins and other substances between cells. These vesicles play a crucial role in cell communication and function, including tissue repair and new blood vessel formation. ExoFlo™ leverages these properties to aid in the treatment of various health conditions.
One of the key applications of ExoFlo™ is in the treatment of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). The product is currently being used in an FDA-approved clinical trial and an FDA-approved Expanded Access Protocol for hospitals. Direct Biologics is also exploring additional clinical applications for its extracellular vesicle products through the FDA's investigational new drug (IND) application process.
Direct Biologics' business model revolves around the development, manufacturing, and sale of its regenerative biologic products. The company generates revenue through the sale of these products to healthcare providers and hospitals.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Dec 2022 | $12M | $255M | Undisclosed | ↗ |
| SERIES AOther financing | Jun 2021 | $51M | $204M | Undisclosed | — |
Growth signals
Latest recorded traffic for Direct biologics is 1.3K monthly website visits, down 60.6% over the last three months. Direct biologics's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Direct biologics in the Austin ecosystem
The Direct biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Direct biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Direct biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










